C43 Stock Chart & Stats
€60.40
€2.60(3.80%)
At close: 4:00 PM EDT
€60.40
€2.60(3.80%)
Day’s Range― - ―
52-Week Range€54.80 - €141.00
Previous CloseN/A
Volume100.00
Average Volume (3M)42.00
Market Cap
€993.20M
Enterprise Value€963.95
Total Cash (Recent Filing)€195.28M
Total Debt (Recent Filing)€4.33M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Mar 24, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding17,543,522
10 Day Avg. Volume40
30 Day Avg. Volume42
Financial Highlights & Ratios
PEG Ratio4.78
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€121.46Price Target Upside101.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.13
Revenue Forecast (FY)€113.31M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetMinimal leverage and substantial equity provide COSMO with financial resilience and flexibility. This capital position can support product development, partnerships, and commercialization while reducing dependence on borrowing and limiting the balance-sheet pressure associated with weaker operating periods.
Diversified Revenue ModelThe combination of direct commercialization and partner-based licensing gives COSMO several routes to monetize its products across territories and indications. Upfront payments, milestones, royalties, and supply income can broaden revenue sources and reduce reliance on one commercialization channel.
Demonstrated Earnings PotentialThe exceptionally strong 2024 result shows that COSMO's portfolio can generate substantial revenue and profitability under favorable conditions. That demonstrated earnings capacity may support reinvestment and partnership activity, even though subsequent results show the performance is not yet consistent.
Bears Say
Sharp Revenue ContractionThe sharp year-over-year revenue decline indicates that recent commercial performance is unstable and difficult to forecast. Sustained volatility can weaken operating leverage, reduce funding available for development, and make it harder to establish a dependable growth trajectory over the coming quarters.
Negative ProfitabilityNegative net and operating margins show that the current revenue base is not covering the full cost of running and developing the business. If this persists, COSMO may need to rely more heavily on its balance-sheet resources, while weaker returns constrain capital allocation and reinvestment.
Cash Burn And Weak Self-FundingThe move from strong positive cash generation in 2024 to operating and free cash outflows in 2025 raises concerns about the quality and sustainability of current earnings. Continued cash burn would reduce internally funded investment capacity and increase reliance on future operating recovery.
COSMO Pharmaceuticals N.V. News
C43 FAQ
What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?
COSMO Pharmaceuticals N.V. lowest stock price was €54.80 and its highest was €141.00 in the past 12 months.
What is COSMO Pharmaceuticals N.V.’s market cap?
COSMO Pharmaceuticals N.V.’s market cap is €993.20M.
When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?
COSMO Pharmaceuticals N.V.’s upcoming earnings report date is Mar 24, 2027 which is in 186 days.
How were COSMO Pharmaceuticals N.V.’s earnings last quarter?
COSMO Pharmaceuticals N.V. released its earnings results on Jul 23, 2026. The company reported -€0.279 earnings per share for the quarter, missing the consensus estimate of €0 by -€0.279.
Is COSMO Pharmaceuticals N.V. overvalued?
According to Wall Street analysts COSMO Pharmaceuticals N.V.’s price is currently Undervalued.
Does COSMO Pharmaceuticals N.V. pay dividends?
COSMO Pharmaceuticals N.V. does not currently pay dividends.
What is COSMO Pharmaceuticals N.V.’s EPS estimate?
COSMO Pharmaceuticals N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSMO Pharmaceuticals N.V. have?
COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.
What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?
COSMO Pharmaceuticals N.V. reported an EPS of -€0.279 in its last earnings report, missing expectations of €0. Following the earnings report the stock price went down -0.292%.
Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?
Currently, no hedge funds are holding shares in DE:C43
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMO Pharmaceuticals N.V.
Cosmo NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
C43 Stock 12 Month Forecast
Average Price Target
€121.46
▲(101.10% Upside)